|
You are here:
Education & Tools
>
|
|
 |
 Conference Highlights |
Antifungal Agents
-
PREVALENCE AND FLUCONAZOLE SUSCEPTIBILITY OF CANDIDA SPP. RECOVERED FROM THE OROPHARYNX OF HEALTH CARE WORKERS AND NON-HEALTH CARE
Klein JD, Levin SM, Steele-Moore L, A.I. Dupont Hospital for Children,
Wilmington, United States
-
EPIDEMIOLOGY OF CLINICAL ISOLATES OF FLUCONAZOLE RESISTANT CANDIDA
Piper J, Couch K, Steele-Moore L, Tuttle D, Christiana Care Health System,
Newark, United States
-
FLUCONAZOLE HETERORESISTANCE IN CANDIDA PARAPSILOSIS
Yamazumi T, Toda H, Iimori M, Akita T, Kitatobe A, Furuta I,
Kinki University, Osakasayama, Japan
-
SUSCEPTIBILITY OF GLOBAL ISOLATES OF CANDIDA SPECIES TO FLUCONAZOLE AND VORICONAZOLE BY DISK DIFFUSION
Sheehan DJ, Pfizer, New York, United States,
The Global Surveillance Group, New York, United States
-
ANTIFUNGAL AGENTS PROBABLY INFLUENCE THE CHANGE OF THE EPIDEMIOLOGY OF FUNGEMIA
Yamakami Y, Tokimatsu I, Karashima R, Nagai H, Kadota J, Nasu M, Hiramatsu K, Saikawa T,
Oita Medical University,
Oita, Japan
-
LOW DOSE LIPOSOMAL AMPHOTERICIN IS EFFECTIVE IN FUNGAL PREVENTION IN ALLOGENEIC STEM CELL TRANSPLANT
Frame D, RUSH Medical Center, Chicago, United States,
Samuel S, Hackensack University Medical Center, Hackensack, United States,
Klingeman H, RUSH Medical Center, Chicago, United States,
Kuyumjian A, Hackensack University Medical Center, Hackensack, United States,
Cicogna C, Hackensack University Medical Center, Chicago, United States,
Drajer D, RUSH Medical Center, Chicago, United States,
Mecca K, Hackensack University Medical Center, Hackensack, United States,
Myint H, RUSH Medical Center, Chicago, United States
-
AMPHOTERICIN B FOR THE TREATMENT OF SYSTEMIC FUNGAL INFECTIONS: A META-ANALYSIS OF CONVENTIONAL VERSUS LIPID FORMULATIONS
MacAulay SS, London Health Sciences Centre, London,
Canada, Martin JE, Lawson Health Research Institute, London, Canada,
Zarnke KB, University of Western Ontario, Ontario, Canada
-
MICAFUNGIN (MCFG), AN ECHINOCANDIN ANTIFUNGAL AGENT FOR THE TREATMENT OF NEW AND REFRACTORY CANDIDEMIA
Ostrosky-Zeichner L, UT Houston Medical School, Houston, United States,
Anaissie E, University of Arkansas, Little Rock, United States,
Kontoyiannia D, UT Houston Medical School, Houston, United States,
Rex JH, UT Houston Medical School, Houston, United States,
Raffalli J, UT Houston Medical School, Houston, United States,
Buell DN, UT Houston Medical School, Houston, United States,
Mullane KM, UT Houston Medical School, Houston, United States,
Vazquez J, UT Houston Medical School, Houston, United States
-
AZOLE TREATMENT OF TWO UNUSUAL PATHOGENS
Durham H, Baumgarten K, Ochsner Clinic Foundation,
New Orleans, United States
-
CASPOFUNGIN (CSP): WHAT MEASURES RESISTANCE?
Hernandez S, Najvar L, Lopez-Ribot J, McCarthy D, Bocanegra
R, Graybill JR, UT Health Sciences Center,
San Antonio, United States
-
CLINICAL EXPERIENCE OF CASPOFUNGIN AND CYCLOSPORIN A (CsA) IN PATIENTS TREATED IN CASPOFUNGIN CLINICAL TRIALS
Kartsonis N, Ngai A, Ryan D, Sable C, Merck Research
Laboratories, Blue Bell,
PA, United States
-
NOVEL ANTIFUNGAL USE IN AN INNER CITY HOSPITAL, A COMPARISON BETWEEN CASPOFUNGIN AND VORICONAZOLE
Gunderson SM, Danziger LH, University of Illinois at Chicago,
Chicago, United States
-
IN VITRO AND IN VIVO ACTIVITY OF ALBACONAZOLE
Alguero M, Merlos M, Boncompte, Bartroli J, R & D Center,
Barcelona, Spain
-
LACK OF QTC EFFECTS OF ALBACONAZOLE, A NEW TRIAZOLE ANTIFUNGAL
De La Cruz G, Perez I, Giral M, Bartroli J, Zquierdo I, Merlos M, R & D Center,
Barcelona, Spain
-
A NOVEL SMALL MOLECULE ANTIFUNGAL COMPOUND WITH IN VIVO ACTIVITY AGAINST ASPERGILLUS FUMIGATUS
Velligan MD, Genelabs Technologies Inc., Redwood City, United States,
Clemons KV, Singh G, Stevens DA, Santa Clara Valley Medical Center and Stanford University, San Jose and Stanford , United States,
Li WB, Botyanszki P, Roberts C, Shi DF, Lou L, Griffith RC, Genelabs Technologies Inc., Redwood City, United States
-
GLYCOSYL AMINO ACID DERIVATIVES AS INHIBITOR OF DNA TOPOISOMERASE I OF CANDIDA ALBICANS
Khan ZK, Jain P, Tripathi RP, Tekwani BL, Central Drug Research,
Philadelphia, United States
-
AMPHOTERICIN B EFFICACY IN THE ACUTE PHASE OF PARACOCCIDIOIDOMYCOSIS: LESSONS FROM A MURINE MODEL
Scavone R, Burger E, Universidade de Sao Paulo,
Sao Paulo, Brazil
|
|